Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report

  • Kim M
  • Jin Y
  • Lee J
  • et al.
N/ACitations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common malignant disease worldwide, and curative treatment remains difficult because the majority of cases are diagnosed in the advanced stage. Sorafenib is the only known effective systemic treatment, but patients rarely achieve complete remission (CR). A 66-year-old man with a history of alcoholic liver cirrhosis with a diagnosis of advanced HCC, was initially treated with transarterial chemoembolization on four occasions. However, the disease progressed with portal vein thrombosis. Therefore, sorafenib was started, and 4 mo later, the patient achieved CR. The treatment was continued for 12 mo, and CR was maintained up to 4 mo after sorafenib discontinuation.

Cite

CITATION STYLE

APA

Kim, M. S., Jin, Y.-J., Lee, J.-W., Lee, J., Kim, Y. S., Lee, S. Y., & Chae, M. H. (2013). Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report. World Journal of Gastrointestinal Oncology, 5(2), 38. https://doi.org/10.4251/wjgo.v5.i2.38

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free